King Pharmaceuticals Now Distributing Bicillin C-R

King Pharmaceuticals has begun distributing its Bicillin C-R injection for patients with penicillin-G-susceptible bacterial infections.

Administered via deep muscular injection, Bicillin C-R is indicated for the treatment of pediatric and adult infections caused by penicillin-G-susceptible bacteria, including moderately severe to severe upper-respiratory tract infections, scarlet fever, erysipelas, streptococci-related skin and soft-tissue infections, and moderately severe pneumonia and ear infections.

“We are now manufacturing and distributing our full line of Bicillin products, which includes Bicillin C-R and Bicillin L-A,” stated Eric J. Bruce, chief technical operations officer, King Pharmaceuticals.

The company announced earlier this year that it is manufacturing and distributing Bicillin L-A (penicillin G benzathine injectable suspension) from its Michigan facility.